alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### UNITED STATES of America, Plaintiff-Appellee, v. Kevin Mark MCQUISTION, Defendant-Appellant.

No. 03-51050.

Summary Calendar

United States Court of Appeals, Fifth Circuit.

April 28, 2004.

Mark Randolph Stelmach, Joseph H. Gay, Jr., Assistant US Attorneys, US Attorney’s Office, San Antonio, TX, for Plaintiff-Appellee.

Thomas S. Morgan, Law Office of Thomas S. Morgan, Midland, TX, for Defendant-Appellant.

Before REAVLEY, JOLLY and DENNIS, Circuit Judges.

PER CURIAM.*

Kevin Mark McQuistion appeals from his conditional guilty-plea conviction for conspiracy to manufacture methamphetamine. McQuistion argues that the district court erred in denying his motion to suppress evidence found in a refrigerator and microwave located on the premises of the Basin Welding Supply Company. The record shows that Charles Joyce, an owner of the Basin Welding Supply Company, had common authority to consent to the police search. *See United States v. Shelton,*337 F.3d 529, 531-32 (5th Cir.2003), *cert. denied,*— U.S.-, 124 S.Ct. 1507, 7158 L.Ed.2d 172 (2004). As a result, the district court correctly denied McQuistion’s motion to suppress evidence.

AFFIRMED.

*

 Pursuant to 5th Cir. R. 47.5, the court has determined that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5th Cir. R. 47.5.4.
---

|CERTIFICATION                                
|---------------------------------------------
|PURSUANT TO                                  
|18 U.S.C. SECTION 1350,                      
|AS ADOPTED PURSUANT TO                       
|SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Jeffrey R. Mason, Chief Financial Officer of Northern
Dynasty Minerals Ltd. (the Company), hereby certify pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that, to the best of my knowledge:

(1) The Annual Report on Form 40-F of
the Company for the fiscal year ended December 31, 2007 (the Annual Report)
fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934, as amended; and

(2) The information contained in the
Annual Report fairly presents, in all material respects, the financial condition
and results of operations of the Company.

| | By:    | /s/ J. Mason           
| | ------ | -----------------------
| |        |                        
| | Name:  | Jeffrey R. Mason       
| | Title: | Chief Financial Officer
| |        |                        
| | Date:  | April 1, 2008          

This written statement is being furnished to the Securities
and Exchange Commission as an exhibit to the Companys Annual Report on Form
40-F. A signed original of this statement has been provided to the Company and
will be retained by the Company and furnished to the Securities and Exchange
Commission or its staff upon request.

This certification accompanies this Annual Report on Form
40-F pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not,
except to the extent required by such Act, be deemed filed by the Company for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act). Such certification will not be deemed to be incorporated by
reference into any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except to the extent that the Company specifically incorporates it
by reference.

---
#### Nicholas Franco et al., Respondents, v Gary H. Zeltser et al., Respondents and Jewish Week and American Examiner, Inc., Appellant.

In an action to vacate or remove a judgment lien on real property, the Jewish Week and the American *368Examiner, Inc. appeals from so much of a judgment of the Supreme Court, Richmond County (Rubin, J.), dated December 9, 1983, as vacated its lien upon the property.

Judgment affirmed, insofar as appealed from, with one bill of costs.

In December 1981, defendant Gary Zeltser signed an affidavit confessing judgment against himself and in favor of appellant the Jewish Week and The American Examiner, Inc. in the amount of $50,000. The sole factual basis for the confession was Mr. Zeltser’s statement that: “This Confession of Judgment is made to assure the return to the said corporation of the aforesaid sums of money which have been taken by me without authority and the return of which I hereby acknowledge I am completely liable”.

On December 21, 1981, appellant entered the confession of judgment in the Richmond County Clerk’s office under the name of Gary *Seltzer.*On July 13,1982, this judgment was satisfied by appellant solely for the purpose of entering a new judgment and thereby correcting the spelling of the debtor’s surname. The corrected judgment was entered on July 15,1982. Thereafter, on August 20, 1982, plaintiffs purchased from the Zeltsers real property which was located in Richmond County. Apparently, a title search conducted on behalf of plaintiffs failed to disclose the presence of the judgment lien on the property. Subsequent to the conveyance, appellant informed plaintiffs of the lien, and they commenced this action to have it set aside. Special Term, finding the affidavit of confession legally deficient under CPLR 3218, vacated the judgment and thus removed the lien. We affirm.

A close reading of the language contained in the affidavit of confession reveals that it failed to meet the factual specificity required under CPLR 3218 (a) (2). Since this absence of facts would prevent interested third parties from ascertaining the bona fides of the circumstances underlying the debt, the judgment must fall (see, *McDaniel v Sangenino,*67 AD2d 698; *County Natl. Bank v Vogt,*28 AD2d 793, *affd*21 NY2d 800).

Moreover, it appears that by the terms of the affidavit of confession itself, appellant was required to file an affidavit by one of its officers that the debt had not been paid as a condition to entering the confession of judgment. This condition was not fulfilled. As such, Special Term acted properly in vacating the lien. We have considered the remaining contentions of the parties and find them to be without merit. Weinstein, J. P., Rubin, Lawrence and Kunzeman, JJ., concur.
I 

109TH CONGRESS 

1ST SESSION H. R. 1860 

To amend the Bankruptcy Abuse Prevention and Consumer Protection Act 

of 2005 to exempt from the means test in bankruptcy cases, for a 

limited period, qualifying reserve-component members who, after September 11, 2001, are called to active duty or to perform a homeland 

defense activity for not less than 60 days. 

IN THE HOUSE OF REPRESENTATIVES 

APRIL 26, 2005 

Mr. ROHRABACHER (for himself and Mr. JONES of North Carolina) introduced 

the following bill; which was referred to the Committee on the Judiciary 

A BILL 

To amend the Bankruptcy Abuse Prevention and Consumer 

Protection Act of 2005 to exempt from the means test 

in bankruptcy cases, for a limited period, qualifying reserve-component members who, after September 11, 

2001, are called to active duty or to perform a homeland 

defense activity for not less than 60 days. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. AMENDMENT. 

4 Section 101(a)(2)(C) of the Bankruptcy Abuse Pre5 vention and Consumer Protection Act of 2005 (Public 

6 Law 109–8) is amended by adding at the end of para-
2 

•HR 1860 IH 

1 graph (2) of section 707(b) of title 11 of the United States 

2 Code, as added by such Act, the following: 

3 ‘‘(E) Subparagraphs (A) through (C) shall not apply, 

4 and the court may not dismiss or convert a case filed 

5 under this chapter based on any form of means testing— 

6 ‘‘(i)(I) while the debtor is on, and during the 

7 180-day period beginning immediately after the 

8 debtor is released from, a period of active duty (as 

9 defined in section 101(d)(1) of title 10) of not less 

10 than 60 days; or 

11 ‘‘(II) while the debtor is performing, and during 

12 the 180-day period beginning immediately after the 

13 debtor is no longer performing, a homeland defense 

14 activity (as defined in section 901(1) of title 32) per15 formed for a period of not less than 60 days; and 

16 ‘‘(ii) if after September 11, 2001, the debtor 

17 while a member of a reserve component of the 

18 Armed Forces or a member of the National Guard, 

19 was called to such active duty or performed such 

20 homeland defense activity.’’. 

21 SEC. 2. EFFECTIVE DATE; APPLICATION OF AMENDMENT. 

22 (a) EFFECTIVE DATE.—Except as provided in sub23 section (b), this Act and the amendment made by this Act 

24 shall take effect on April 20, 2005. 
3 

•HR 1860 IH 

1 (b) APPLICATION OF AMENDMENTS.—The amend2 ment made by this Act shall apply only with respect to 

3 cases commenced under title 11 of the United States Code 

4 after April 20, 2005. 

Æ
EXHIBIT 32.1
 WRITTEN STATEMENT
PURSUANT TO
18 U.S.C. SECTION 1350
  (i)
    
    the Companys Quarterly Report on Form 10-Q for the quarter ended September
30, 2009 (the Report) fully complies with the requirements of section 13(a) and
15(d) of the Securities Exchange Act of 1934; and(ii)
    
    the information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.
 Dated: November 6, 2009
    /S/ Steven F. Udvar-HazySTEVEN F. UDVAR-HAZYDated: November 6, 2009
    /S/ Alan H. LundALAN H. LUND
```

[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2179 Introduced in House (IH)]

109th CONGRESS
  1st Session
                                H. R. 2179

To extend the suspension of duty on hexanedioic acid, polymer with 1,3-
                         benzenedimethanamine.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                              May 5, 2005

  Mr. Forbes introduced the following bill; which was referred to the 
                      Committee on Ways and Means

_______________________________________________________________________

                                 A BILL

 
To extend the suspension of duty on hexanedioic acid, polymer with 1,3-
                         benzenedimethanamine.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. HEXANEDIOIC ACID, POLYMER WITH 1,3-BENZENEDIMETHANAMINE.

    (a) Amendment.--Heading 9902.01.71 of the Harmonized Tariff 
Schedule of the United States (relating to hexanedioic acid, polymer 
with 1,3-benzenedimethanamine) is amended by striking ``12/31/2006'' 
and inserting ``12/31/2008''.
    (b) Effective Date.--
            (1) In general.--The amendment made by subsection (a) 
        applies to goods entered, or withdrawn from warehouse for 
        consumption, on or after the 15th day after the date of the 
        enactment of this Act.
            (2) Retroactive application.--If the date of the enactment 
        of this Act occurs on or after January 1, 2007, then 
        notwithstanding section 514 of the Tariff Act of 1930 (19 
        U.S.C. 1514) or any other provision of law, and upon proper 
        request filed with the Bureau of Customs and Border Protection 
        not later than 180 days after the date of the enactment of this 
        Act, any entry, or withdrawal from warehouse for consumption, 
        of goods described in heading 9902.01.71 of the Harmonized 
        Tariff Schedule of the United States which--
                    (A) was made after December 31, 2006, and before 
                the date of the enactment of this Act, and
                    (B) would have been subject to no duty had the 
                amendment made by subsection (a) been in effect on the 
                date of such entry or withdrawal,
        shall be liquidated or reliquidated as if the amendment made by 
        subsection (a) applied to such entry or withdrawal.
                                 <all>
```
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM
COMPAQ COMPUTER CORPORATION'S CONSOLIDATED BALANCE SHEET AND CONSOLIDATED
STATEMENT OF INCOME FOR THE PERIOD ENDED MARCH 31, 1997 AND IS QUALIFIED
IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-END>                               MAR-31-1997
<CASH>                                           4,554
<SECURITIES>                                       194
<RECEIVABLES>                                    2,710
<ALLOWANCES>                                         0
<INVENTORY>                                      1,268
<CURRENT-ASSETS>                                 9,586
<PP&E>                                           1,195
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                  10,973
<CURRENT-LIABILITIES>                            3,896
<BONDS>                                            300
<COMMON>                                         1,126
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                       5,424
<TOTAL-LIABILITY-AND-EQUITY>                    10,973
<SALES>                                          4,805
<TOTAL-REVENUES>                                 4,805
<CGS>                                            3,627
<TOTAL-COSTS>                                    3,627
<OTHER-EXPENSES>                                   122<F1>
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                  32
<INCOME-PRETAX>                                    569
<INCOME-TAX>                                       182
<INCOME-CONTINUING>                                387
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       387
<EPS-PRIMARY>                                     1.36
<EPS-DILUTED>                                     1.36
<FN>
<F1> Includes research and development costs.
</FN>
        


</TABLE>
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Allergy and Infectious Diseases Special Emphasis Panel; New Technologies for the In Vivo Delivery of Gene Therapeutics for an HIV Cure (R01 Clinical Trial Not Allowed).                    

*Date:*                         July 16, 2021.                    

*Time:*                         10:00 a.m. to 6:00 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G22B, Rockville, MD 20892, (Virtual Meeting).                    

*Contact Person:*                         Kristina S. Wickham, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G22B, Rockville, MD 20852, 301-761-5390,                         *kristina.wickham@nih.gov*.                    

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: June 17, 2021.

Tyeshia M. Roberson,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2021-13219 Filed 6-23-21; 8:45 am]

BILLING CODE 4140-01-P
Exhibit
31.4
  PROCERA
NETWORKS, INC.
  CERTIFICATION
OF CHIEF FINANCIAL OFFICER
 PURSUANT
TO RULE 13a-14(a) AND 15d-14(a) OF
 THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
  I, Thomas
H. Williams, certify that:
  1.      I
have reviewed this Amendment No. 1 to Annual Report on Form 10-K/A of PROCERA
NETWORKS, Inc. and
  2.      Based
on my knowledge, this report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading
with respect to the period covered by this report.
  
 By:
              /s/
      Thomas H. WilliamsThomas
      H. WilliamsVice
      President and Chief Financial OfficerDate:
              April
      29, 2008
[No. 15395-9-III.

Division Three.

September 23, 1997.]

#### The State of Washington, *Respondent,*v. William Joseph Trujillo, *Appellant.*

Appeal from a judgment of the Superior Court for Yakima County, No. 95-1-00992-7, Michael W. Leavitt, J., entered November 30, 1995. *Affirmed*by unpublished opinion per Kurtz, J., concurred in by Schultheis, A.C.J., and Thompson, J.
[No. 37998-4-I.

Division One.

September 22, 1997.]

#### Scott Mantz Associates, Inc., Respondent, v. Enayat Aziz, et al., *Appellants.*

Appeal from, a judgment of the Superior Court for King County, No. 95-2-13922-1, Jim Bates, J., entered December 11, 1995. *Affirmed*by unpublished per curiam opinion.
[No. 38384-1-I.

Division One.

August 4, 1997.]

#### Georgia A. Gardner, *Appellant,*v. Joseph Mark Olson, et al., *Respondents.*

Appeal from a judgment of the Superior Court for What-com County, No. 95-2-00667-8, Michael F. Moynihan, J., entered February 28, 1996. *Affirmed*by unpublished opinion per Agid, J., concurred in by Grosse and Cox, JJ.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS FOR THE SECOND QUARTER OF FISCAL 2000 AS FILED IN THE
COMPANY'S FORM 10-Q FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2000.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          SEP-30-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               MAR-31-2000
<CASH>                                         130,454
<SECURITIES>                                    44,714
<RECEIVABLES>                                  148,815
<ALLOWANCES>                                     5,344
<INVENTORY>                                    213,184
<CURRENT-ASSETS>                               582,840
<PP&E>                                         391,102
<DEPRECIATION>                                 195,160
<TOTAL-ASSETS>                                 791,571
<CURRENT-LIABILITIES>                          174,931
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                     14,976
<COMMON>                                       416,015
<OTHER-SE>                                     151,151
<TOTAL-LIABILITY-AND-EQUITY>                   791,571
<SALES>                                        204,596
<TOTAL-REVENUES>                               204,596
<CGS>                                          115,603
<TOTAL-COSTS>                                  115,603
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 416
<INCOME-PRETAX>                                 17,829
<INCOME-TAX>                                     6,218
<INCOME-CONTINUING>                             11,611
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    11,611
<EPS-BASIC>                                     0.35
<EPS-DILUTED>                                     0.32


</TABLE>
```

[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2020 Introduced in House (IH)]

109th CONGRESS
  1st Session
                                H. R. 2020

            To suspend temporarily the duty on Uniconazole.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             April 28, 2005

Mrs. Tauscher introduced the following bill; which was referred to the 
                      Committee on Ways and Means

_______________________________________________________________________

                                 A BILL

 
            To suspend temporarily the duty on Uniconazole.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. UNICONAZOLE.

    (a) In General.--Subchapter II of chapter 99 of the Harmonized 
Tariff Schedule of the United States is amended by inserting in 
numerical sequence the following new heading:

``      9902.06.19       (E)-(+)-(S)-1-(4-  Free         No change        No change        On or before 12/  ''.
                         Chlorophenyl)-4,4-                                                 31/2008
                         dimethyl-2-(1,2,4-
                         triazol-1-yl)pent-
                         1-en-3-ol
                         (Uniconazole)
                         (CAS No. 83657-17-
                         4) (provided for
                         in subheading
                         3808.30.15)......

    (b) Effective Date.--The amendment made by subsection (a) applies 
to goods entered, or withdrawn from warehouse for consumption, on or 
after the 15th day after the date of the enactment of this Act.
                                 <all>
```
#### In the Matter of Samuel L. Sommer, Respondent, v Harold J. Smith, as Superintendent of Attica Correctional Facility, et al., Appellants.

— Judgment unanimously affirmed *(see, Matter of Jones v Smith,*120 Misc 2d 445, *affd*101 AD2d 705, *lv granted*63 NY2d 601). (Appeal from judgment of Supreme Court, Wyoming County, Horey, J. — art 78.) Present — Dillon, P. J., Doerr, Denman, Boomer and Schnepp, JJ.